| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CCLE | pan-cancer | AAC | 0.037 | 0.4 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.4 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | 0.024 | 0.4 |
| mRNA | AZD-2281 | FIMM | pan-cancer | AAC | 0.13 | 0.4 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | XL765 | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | momelotinib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |